No Data
Express News | Modern Chinese Medicine Group FY Revenue RMB 214.1 Million
Express News | Modern Chinese Medicine Group FY Pretax Profit RMB 14.8 Million
MODERN CHI MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
[Brokerage Focus] CITIC SEC: The integration of the Traditional Chinese Medicine Industry is accelerating, and the leading players are expected to strengthen their position.
Jinwu Financial News | CITIC SEC states that the price of Traditional Chinese Medicine materials has entered a downward channel, and improvements in industrial costs are worth anticipating. Starting in January 2025, Traditional Chinese Medicine companies will successively complete inventory clearance through channels, and numerous e-commerce activities will occur during the Spring Festival, with strong purchasing power among Consumers. The e-commerce platforms' sales of Pharmaceutical products generally achieve high year-on-year growth rates. Benefiting from policy support and the accelerated aging of the population, the bank expects that overall demand for Traditional Chinese Medicine will continue to improve in the future, with industry consolidation accelerating, and leading companies are likely to become stronger.
Hong Kong stock Concept tracking | Promoting the value assessment and allocation of Traditional Chinese Medicine Pharmaceuticals, Institutions are Bullish on the recovery of Traditional Chinese Medicine revenue (with attached Concept stocks)
The General Office of the State Council issued the "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry."
MODERN CHI MED (01643.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.
Gelonghui, March 14 - MODERN CHI MED (01643.HK) announced that it will hold a Board of Directors meeting on March 26, 2025 (Wednesday), the agenda of which includes considering and approving the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and considering the proposal for the distribution of a final dividend (if any).
